Nventa's HspE7 shown safe in PhI trial
USA-based Nventa Pharmaceuticals has announced positive safety and tolerability results in the final cohort of its Phase I trials for lead candidate HspE7, indicated to treat cervical intraepithelial neoplasia.
In total, four cohorts were administered escalating doses of adjuvant and the candidate was well tolerated in each. Additionally, the treatment showed a promising immune response, boding well for the potential application of the compound.
HspE7 is a novel therapeutic candidate for the treatment of precancerous and cancerous lesions caused by the human papillomavirus (HPV). The firm believes the product can treat CIN by enhancing the body's natural immune system. It is currently being evaluated to treat other HPV-associated cancers.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze